San Francisco, Oct 30 : A new multicenter study presented at TCT 2025, the world’s leading scientific symposium on interventional cardiology, has found that next-generation ultrathin drug-eluting stents are both safe and effective in diabetic patients with multivessel coronary artery disease (MVD) — a group often considered for bypass surgery.

The TUXEDO-2 trial compared outcomes of percutaneous coronary intervention (PCI) using two contemporary drug-eluting stents: a biodegradable polymer-coated sirolimus-eluting stent (BP-SES) and a durable-polymer everolimus-eluting stent (DP-EES).

Conducted across multiple centers in India, the prospective, open-label, randomized trial enrolled 1,800 patients with diabetes and multivessel disease. Participants were randomized equally to receive eith

See Full Page